E Ffector Therapeutics, Inc. EFTR
We take great care to ensure that the data presented and summarized in this overview for eFFECTOR Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EFTR
View all-
Abingworth LLP London, X04.82MShares$00.69% of portfolio
-
Oup Management Co., LLC1.03MShares$01.38% of portfolio
-
Evolution Capital Management LLC Crystal Bay, NV528KShares$01.04% of portfolio
-
Blackstone Inc New York, NY52.3KShares$00.0% of portfolio
-
Resolute Financial, LLC31KShares$00.01% of portfolio
Latest Institutional Activity in EFTR
Top Purchases
Top Sells
About EFTR
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
Insider Transactions at EFTR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 15
2024
|
Stephen T Worland Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,806
+12.63%
|
$1,806
$1.68 P/Share
|
|
May 15
2024
|
Michael Byrnes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,387
+30.79%
|
$1,387
$1.68 P/Share
|
|
Nov 27
2023
|
Sr One Capital Management, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
609,163
-8.93%
|
$0
$0.61 P/Share
|
|
Nov 15
2023
|
Stephen T Worland Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,979
+2.19%
|
$0
$0.5 P/Share
|
|
Nov 15
2023
|
Michael Byrnes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,524
+9.47%
|
$0
$0.5 P/Share
|
|
Aug 11
2023
|
Stephen T Worland Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,799
+11.46%
|
$0
$0.52 P/Share
|
|
May 15
2023
|
Michael Byrnes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,863
+11.15%
|
$0
$0.46 P/Share
|
|
May 15
2023
|
Stephen T Worland Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,401
+2.74%
|
$0
$0.46 P/Share
|
|
Nov 15
2022
|
Michael Byrnes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,651
+12.07%
|
$0
$0.47 P/Share
|
|
Nov 15
2022
|
Stephen T Worland Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,047
+2.66%
|
$0
$0.47 P/Share
|
|
Oct 04
2022
|
Christopher B Ehrlich |
BUY
Open market or private purchase
|
Direct |
346
+0.97%
|
$0
$0.57 P/Share
|
|
Sep 26
2022
|
Christopher B Ehrlich |
BUY
Open market or private purchase
|
Direct |
18,867
+35.11%
|
$0
$0.55 P/Share
|
|
Aug 03
2022
|
Presidio Management Group X LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
59,376
-1.41%
|
$0
$0.8 P/Share
|
|
Aug 02
2022
|
Presidio Management Group X LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
28,201
-0.66%
|
$0
$0.8 P/Share
|
|
Aug 01
2022
|
Presidio Management Group X LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
26,703
-0.62%
|
$0
$0.79 P/Share
|
|
Jul 28
2022
|
Presidio Management Group X LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
32,517
-0.76%
|
$0
$0.89 P/Share
|
|
Jul 27
2022
|
Presidio Management Group X LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
43,665
-1.0%
|
$0
$0.89 P/Share
|
|
Jul 26
2022
|
Presidio Management Group X LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,775
-0.06%
|
$0
$0.9 P/Share
|
|
Jul 25
2022
|
Presidio Management Group X LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,279
-0.05%
|
$0
$0.93 P/Share
|
|
Jul 22
2022
|
Presidio Management Group X LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
7,614
-0.17%
|
$0
$0.91 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 3.19K shares |
|---|